國林科技(300786.SZ):2022年度擬向銀行申請不超5.8億元綜合授信額度
格隆匯3月17日丨國林科技(300786.SZ)公佈,為滿足公司生產經營和發展的需要,公司2022年度擬向銀行申請授信總金額不超過人民幣5.8億元(最終以各家銀行實際審批的授信額度為準),具體授信品種及額度分配、授信的期限、具體授信業務的利率、費率等條件以公司根據資金使用計劃與銀行簽訂的最終授信協議為準,並提請股東大會授權公司董事長及管理層全權辦理此次銀行授信相關工作。有效期自2021年年度股東大會審批通過之日起至公司2022年年度股東大會召開之日止,在授信期限內,授信額度可循環使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.